Recent progress in therapeutic applications of chalcones.
about
The chalcone derivative (E)-1-(4-fluoro-phen-yl)-3-(4-hy-droxy-3-meth-oxy-phen-yl)prop-2-en-1-one monohydrate.Regiospecificity of human UDP-glucuronosyltransferase isoforms in chalcone and flavanone glucuronidation determined by metal complexation and tandem mass spectrometry.Biological Effect of Licochalcone C on the Regulation of PI3K/Akt/eNOS and NF-κB/iNOS/NO Signaling Pathways in H9c2 Cells in Response to LPS Stimulation.Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation.Influence of S-Oxidation on Cytotoxic Activity of Oxathiole-Fused Chalcones.Structural factors affecting cytotoxic activity of (E)-1-(Benzo[d ][1,3]oxathiol-6-yl)-3-phenylprop-2-en-1-one derivatives.Pharmacokinetic Studies of Oxathio-Heterocycle Fused Chalcones.Crystal structure of (E)-2-[(2-bromopyridin-3-yl)methyl-idene]-6-meth-oxy-3,4-di-hydro-naphthalen-1(2H)-one and 3-[(E)-(6-meth-oxy-1-oxo-1,2,3,4-tetra-hydro-naphthalen-2-ylidene)meth-yl]pyridin-2(1H)-one.Novel pyrazine analogs of chalcones: synthesis and evaluation of their antifungal and antimycobacterial activity.(2E)-3-(4-Methyl-phen-yl)-1-(pyridin-3-yl)prop-2-en-1-oneOpening or closing the lock? When reactivity is the key to biological activity.Reactivity assessment of chalcones by a kinetic thiol assay.Activation of Nrf2-driven antioxidant enzymes by cardamonin confers neuroprotection of PC12 cells against oxidative damage.Chemical characterisation and hepatoprotective potential of Cosmos sulphureus Cav. and Cosmos bipinnatus Cav.Isobavachalcone from Angelica keiskei Inhibits Adipogenesis and Prevents Lipid Accumulation.Preparation and ion recognition features of porphyrin–chalcone type compounds as efficient red-fluorescent materials
P2860
Q36775919-365760F9-2CB5-461D-8009-B6B05E76148CQ37010122-EFC5AC5E-A0ED-4E9B-9EC4-B1EEE92CE16FQ38711071-698667EE-B519-4A12-AE5F-E36562CCAEB0Q38733237-D7EC4EC3-D511-4420-BC09-F7305B06E080Q38769760-F333B086-3D8D-4874-B830-CF8745B3EC0CQ39029255-96DADF1B-C875-4A70-B462-79DA6F66FB1AQ40055852-6A69655D-6F73-446B-85E4-70DC3A9033B8Q41473500-2EA6DB4B-2430-4265-82C9-19F1DC4B3999Q41545511-A183FDA6-2932-4D43-9876-9141838C88A5Q42267955-1936C646-0ED0-4957-9044-71DC9E3FF420Q44416722-E05920B9-054D-4C94-8073-6DDDBBA072D7Q44885086-3806982A-34EA-42C4-9BAD-FC79988A4861Q46407584-58D85991-EDDC-49CA-80A3-4AF088EC43B0Q49968404-7BC8E2FE-1558-4FD5-A587-F1552568386BQ55669275-3F24F0DF-0C36-4A5F-BC0D-B5063158E90DQ57528851-27BCDE70-0080-40CB-B0ED-434E1BC0C4FC
P2860
Recent progress in therapeutic applications of chalcones.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent progress in therapeutic applications of chalcones.
@en
Recent progress in therapeutic applications of chalcones.
@nl
type
label
Recent progress in therapeutic applications of chalcones.
@en
Recent progress in therapeutic applications of chalcones.
@nl
prefLabel
Recent progress in therapeutic applications of chalcones.
@en
Recent progress in therapeutic applications of chalcones.
@nl
P2860
P1476
Recent progress in therapeutic applications of chalcones.
@en
P2093
Anna-Maria Katsori
Dimitra Hadjipavlou-Litina
P2860
P304
P356
10.1517/13543776.2011.596529
P407
P577
2011-06-28T00:00:00Z